FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans
InspiredImages / Pixabay

FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans

According to a story from Business Wire, the biopharmaceutical company Onspira Therapeutics recently announced that its investigational therapy OSP-101 was recently granted Orphan Drug designation by the US Food and…

Continue Reading FDA Grants Orphan Drug Designation to Onspira Therapeutics’ Investigational Interleukin-1 Receptor Antagonist for the Treatment of Bronchiolitis Obliterans
Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
jarmoluk / Pixabay

Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA

According to a story from Globe Newswire, the biotechnology company Wave Life Sciences recently announced that its investigational product WVE-210201 has received both Rare Pediatric disease designation and Orphan Drug…

Continue Reading Experimental Duchenne Muscular Dystrophy Drug Gets Multiple Designations From the FDA
Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa
LaCasadeGoethe / Pixabay

Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa

Two companies, GtreeBNT and YuYang DNU, will collaborate in a joint venture to develop the investigational drug RGN-137 for the treatment of epidermolysis bullosa. For more details, you can read…

Continue Reading Two Companies are Collaborating to Develop an Investigational Drug for Epidermolysis Bullosa